GLEIF
10.12.2020 09:57:09 CET | Business Wire | Press release
The Global Legal Entity Identifier Foundation (GLEIF) is to extend the Global LEI System to create a fully digitized LEI service capable of enabling instant and automated identity verification between counterparties operating across all industry sectors, globally.
Following a series of 2020 research initiatives, GLEIF today invites stakeholders from across the digital economy to engage in a cross industry development program to create an ecosystem and credential governance framework, together with a technical supporting infrastructure, for a verifiable LEI (vLEI), a digitally verifiable credential containing the Legal Entity Identifier (LEI).
By embedding new and existing LEIs in Verifiable Credentials1 , the vLEI will create a cryptographically secure chain of trust that replaces today’s manual processes required to access and confirm an entity’s LEI data.
The vLEI will give government organizations, companies and other legal entities worldwide the capacity to use non-repudiable identification data pertaining to their legal status, ownership structure and authorized representatives in a growing number of digital business activities, such as approving business transactions and contracts, onboarding customers, transacting within import/export and supply chain business networks and submitting regulatory filings and reports.
“The global LEI system is unique in its capacity to provide regulated and standardized global identities for legal entities everywhere,” comments Stephan Wolf, CEO, GLEIF. “Our next step is to secure the process of presenting and verifying LEI data digitally, so it can be used across the digital economy in corporate ID use-cases. This year, GLEIF has begun exploring technical approaches across a number of industry sectors, with the aim of identifying an open and universally interoperable model. We’re excited to now formalize the vLEI development program and invite broader engagement to help us unlock the power of the LEI for all industry sectors around the world.”
Drummond Reed, Steering Committee Member, Trust-over-IP-Foundation, comments: “The vLEI has the potential to become one of the most valuable digital credentials in the world because it is the hallmark of authenticity for a legal entity of any kind. The family of digital credentials in the GLEIF vLEI Governance Framework can serve as a chain of trust for anyone needing to verify the legal identity of an organization or of a person legally acting on that organization’s behalf. The demand this will create for LEIs — and the impact it will have on adoption of self-sovereign identity — cannot be overestimated. It will be a sea change for digital trust infrastructure that will benefit every country, company, and citizen in the world.”
GLEIF is already engaged in research partnerships and technical trials with stakeholders in pharmaceutical, healthcare, telecom, automotive and financial services sectors. A range of blockchain, self-sovereign identity and other decentralized key management propositions are currently being explored.
Chris Ingrao, Chief Strategy Officer of Lumedic, a Tegria company, a US-based Health Information Logistics firm piloting the vLEI, comments: “Lumedic recently launched the Lumedic Exchange, the first healthcare ecosystem of its kind dedicated solely to community-driven standards development for patient-intermediated information exchange using verifiable credentials. It is attracting a multinational membership from a broad array of industries and needs to ensure all members are fully registered legal entities with strong accountability. The vLEI will enable us to standardize on a digital credential attesting to that status from all Lumedic Exchange members providing both efficiency and assurance.”
Steve Meizanis, Global Product Head of Symbology and LEI Services at Bloomberg LP, comments: “Bloomberg’s two vLEI proof-of-concept trials signal a clear opportunity to broaden the usage and increase adoption of the LEIs in digitized corporate activities. It also increases the scope for new and existing LEI issuers to offer vLEI services, strengthening the Global LEI System as a whole.”
GLEIF has collaborated with Deloitte to identify that demand generation for the vLEI will occur through a combination of existing LEI use-cases, including regulatory mandates for financial reporting, growth market segments in relation to new use-cases, such as Know Your Customer (KYC) procedures, and the broader digital economy, including strong anticipated growth in the area of self-sovereign Identity-enabled business ecosystems.
Derek Ryan, Partner, Deloitte, comments: “This is an exciting time for the self-sovereign identity industry. Universally trusted digital identities among both businesses and individuals are set to play a central role in our fast-evolving digital economy. Until now the absence of a trusted governance authority able to link digital identities with real world legal entities has presented an industry-wide barrier to innovation. GLEIF is very well positioned to overcome this barrier by extending the LEI as a critical component of the global digital economy. The potential value that will be unlocked by the vLEI is substantial, as it enables government authorities and identity service providers to embrace efficient new digital platforms, create new digital ecosystems and to end the reliance on repetitive manual identity verification steps which account for high annual costs across the global economy.”
-ENDS-
Additional GLEIF partner quotes supporting the vLEI
“The use of the LEI for fully distributed verifiable credentials provides a missing capability in distributed identity. The value extends far beyond financial services to e-commerce, trade services, and governmental reporting. The LEI in this way reinforces the value the ISO 17442 standard as the world of organizational identity in the digital world evolves.”
Jim Northey, Chair, ISO TC 68
“Obtaining a vLEI needs to be a core element to every company’s digital transformation strategy. This is especially true with any organization that works with financial and health data. Consumers and partners need to be able to trust and verify the identity of these organizations. We are committed to leveraging the combination of vLEIs, verified credentials standards, and cryptographic key management to drive broad scale adoption of digital identities, profiles, and the BurstIQ secure data network that was purpose built to exchange identity and health data.”
Frank Ricotta, CEO, BurstIQ
“Provenant is delighted to be working with GLEIF to help introduce verifiable Legal Entity Identifiers (vLEI) to the telecom industry. Telecom struggles to consistently identify originators of voice calls and messages, resulting in robocalls and spam. We believe GLEIF's effectiveness as a global root of trust for the financial sector could powerfully address cross-channel, cross-jurisdictional trust challenges faced by the telecom industry. We look forward to working with GLEIF to develop new solutions that utilize GLEIF and the vLEI to bring new levels of trust and verifiability to communications networks globally.”
Randy Warshaw, Founder, Provenant
Full resolution images and logos can be downloaded via this link
https://www.gleif.org/en/newsroom/gleif-graphics-images
Relevant link
https://www.gleif.org/en
1 ‘Verifiable Credential’ is defined by the Worldwide Web Consortium’s Verifiable Credentials Working Group here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
